GLP-1 Medications May Reduce Risk of Addiction, Study Finds

A large-scale study of US veterans suggests that medications commonly prescribed for type 2 diabetes may also be associated with a reduced risk of substance use disorders, revealing a surprising connection between metabolic treatments and addiction vulnerability.

Unexpected Link Between Diabetes Treatment and Addiction Risk

Researchers examining the effects of initiating glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) among United States veterans with type 2 diabetes (T2D) found that individuals starting these drugs had a lower risk of developing substance use disorders (SUDs). The medications were also linked to fewer adverse outcomes, including SUD-related hospitalizations, overdose events, and suicidal ideation, among those already living with such conditions. The research was published in the British Medical Journal.

How GLP-1 RAs Might Impact Addiction

Growing evidence suggests that GLP-1 RAs may affect brain pathways linked to addiction. Preclinical research indicates these medications may cross the blood-brain barrier and act on regions involved in reward, motivation, and impulse control, potentially influencing dopamine signaling in the brain’s reward circuitry. Studies have shown GLP-1 RAs may reduce the reinforcing effects of substances like nicotine, alcohol, opioids, and cocaine.

Study Design and Veteran Cohort

The cohort study analyzed electronic health record data from 606,434 US veterans with T2D receiving care through the Department of Veterans Affairs (VA) healthcare system. Participants included veterans with and without a prior history of SUDs. Researchers excluded individuals with certain contraindications, such as gastroparesis or diabetic ketoacidosis.

Key Findings: Reduced Risk Across Multiple Substances

Compared to initiating sodium-glucose cotransporter 2 (SGLT-2) inhibitors, initiating GLP-1 RAs was associated with:

• An 18% decreased risk of alcohol use disorder.
• A 20% decreased risk of cocaine use disorder.
• An 18% decreased risk of nicotine use disorder.
• A 14% decreased risk of cannabis use disorder.
• A decreased risk of opioid use disorder (75% reduction).
• A decreased risk of other substance use disorders.

Among veterans already living with SUDs, GLP-1 RA initiation was linked to reduced rates of SUD-associated emergency department visits, hospitalizations, overdose events, suicidal ideation, and SUD-related mortality.

Study Limitations and Future Research

Researchers emphasize that this was an observational study and cannot establish causation. The study population was predominantly older male veterans, limiting generalizability. Residual confounding, despite statistical adjustments, cannot be entirely excluded. Further research is needed to confirm these findings in broader populations and to understand the underlying mechanisms.

Potential Implications for Addiction Treatment

These findings highlight the potential for GLP-1 RAs to play a role in both the prevention and management of substance use disorders, particularly for individuals with diabetes who are also at risk for or experiencing addiction. Clinicians should weigh potential benefits against known adverse effects and engage in individualized clinical decision-making.

Expert Commentary

Gareth Jones, director of corporate affairs at the National Pharmacy Association, noted that the study suggests weight loss treatment may have important additional therapeutic benefits.